Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision
Adds To Hemophilia A Problems
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.
You may also be interested in...
Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.
Co-Inventor Of mRNA Tech Goes After Sickle Cell Anemia
After a chance encounter at a photocopy machine brewed the recipe for Pfizer and Moderna’s success with mRNA vaccines, Dr Drew Weissman has set sights on developing a single-injection therapy for sickle cell anemia.
Enjaymo Marks Latest Milestone In Sanofi’s Blood Disorder Effort
The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.